Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients

Cancer Science

Volumn 102, Issue 2, 2011, Pages 439-445

  Ibusuki, Mutsuko ^a   Yamamoto, Yutaka ^a   Shinriki, Satoru ^b   Ando, Yukio ^b   Iwase, Hirotaka ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIESTROGEN; AROMATASE INHIBITOR; CAPECITABINE; CYCLIN E; HORMONE RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA; MYC PROTEIN; NAVELBINE; TRASTUZUMAB; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE FBXW1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL FUNCTION; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LABELING INDEX; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL SEPARATION; F-BOX PROTEINS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES;

EID: 79952094707     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01801.x     Document Type: Article

References (36)

1. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001; 413: 316-22.
2. Chen C, Seth AK, Aplin AE. Genetic and expression aberrations of E3 ubiquitin ligases in human breast cancer. Mol Cancer Res 2006; 4: 695-707.
3. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008; 8: 83-93.
4. Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 2000; 83: 1688-95.
5. Keyomarsi K, Tucker SL, Buchholz TA et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347: 1566-75.
6. Onoyama I, Nakayama KI. Fbxw7 in cell cycle exit and stem cell maintenance: insight from gene-targeted mice. Cell Cycle 2008; 7: 3307-13.
7. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006; 6: 369-81.
8. Ekholm-Reed S, Spruck CH, Sangfelt O et al. Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer. Cancer Res 2004; 64: 795-800.
9. Tsunematsu R, Nakayama K, Oike Y et al. Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J Biol Chem 2004; 279: 9417-23.
10. Onoyama I, Tsunematsu R, Matsumoto A et al. Conditional inactivation of Fbxw7 impairs cell-cycle exit during T cell differentiation and results in lymphomatogenesis. J Exp Med 2007; 204: 2875-88.
11. Akhoondi S, Sun D, von der Lehr N et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 2007; 67: 9006-12.
12. Byrd KN, Huey B, Roydasgupta R, Fridlyand J, Snijders AM, Albertson DG. FBXW7 and DNA copy number instability. Breast Cancer Res Treat 2008; 109: 47-54.
13. Hagedorn M, Delugin M, Abraldes I et al. FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients. Cell Div 2007; 2: 9.
14. Yokobori T, Mimori K, Iwatsuki M et al. p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res 2009; 69: 3788-94.
15. Iwatsuki M, Mimori K, Ishii H et al. Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance. Int J Cancer 2010; 126: 1828-37.
16. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19: 3817-27.
17. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-65.
18. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-83.
19. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-44.
20. Yamamoto Y, Ibusuki M, Okumura Y et al. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat 2008; 110: 465-75.
21. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
22. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74.
23. Yu JC, Ding SL, Chang CH et al. Genetic susceptibility to the development and progression of breast cancer associated with polymorphism of cell cycle and ubiquitin ligase genes. Carcinogenesis 2009; 30: 1562-70.
24. Gu Z, Mitsui H, Inomata K et al. The methylation status of FBXW7 beta-form correlates with histological subtype in human thymoma. Biochem Biophys Res Commun 2008; 377: 685-8.
25. Xu Y, Sengupta T, Kukreja L, Minella AC. MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7. J Biol Chem 2010; 285: 34439-46.
26. Buckley MF, Sweeney KJ, Hamilton JA et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993; 8: 2127-33.
27. Schlotter CM, Vogt U, Bosse U, Mersch B, Wassmann K. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res 2003; 5: R30-6.
28. Al-Kuraya K, Schraml P, Torhorst J et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004; 64: 8534-40.
29. Scorilas A, Yotis J, Pateras C, Trangas T, Talieri M. Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. Clin Cancer Res 1999; 5: 815-21.
30. Le MG, Mathieu MC, Douc-Rasy S et al. c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int J Cancer 1999; 84: 562-7.
31. Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 1995; 221: 706-18; discussion 18-20.
32. Callagy GM, Pharoah PD, Pinder SE et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006; 12: 2468-75.
33. Efstratiadis A, Szabolcs M, Klinakis A. Notch, Myc and breast cancer. Cell Cycle 2007; 6: 418-29.
34. Wang L, Shao ZM. Cyclin e expression and prognosis in breast cancer patients: a meta-analysis of published studies. Cancer Invest 2006; 24: 581-7.
35. Lai A, Sarcevic B, Prall OW, Sutherland RL. Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell Cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1). J Biol Chem 2001; 276: 25823-33.
36. Mukherjee S, Conrad SE. c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem 2005; 280: 17617-25.